This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV1246

Pregabalin augmentation in patients with schizophrenia

PREGABALIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA

In six patients with schizophrenia who had a partial response to quetiapine, pregabalin augmentation was associated with a marked reduction in anxiety measures after eight weeks.

The aim of the study was to evaluate the efficacy and tolerability of pregabalin augmentation for anxiety in schizophrenia over an eight-week follow-up. The sample consisted of six male outpatients diagnosed with schizophrenia according to ICD-10, with a mean age of 42.8 years; all had received quetiapine 300 mg/day for an adequate duration and had shown a partial response. In three patients, pregabalin was gradually added to their existing antipsychotic treatment and titrated to 600 mg/day over four weeks, while the other three patients continued quetiapine monotherapy at 300 mg/day; efficacy was assessed at four-week intervals using the Hamilton Anxiety Rating Scale (HAM-A), the Positive and Negative Syndrome Scale (PANSS), and the Clinical Global Impression (CGI) scale. The mean reduction in HAM-A scores in the pregabalin group was 13.2 points; a significant reduction in HAM-A scores was observed from baseline to week eight, and CGI scores favored pregabalin four weeks after augmentation began. According to the comparison table in the poster, the pregabalin group showed marked reductions in psychic anxiety and subjective tension, mild improvements in the negative symptom and general psychopathology domains of the PANSS, and reductions in sleep latency and nocturnal awakenings; changes in the monotherapy group were minimal, with symptoms remaining at baseline levels. Safety and tolerability were rated as equivalent for the two medications. The authors note that, in this sample of six patients, pregabalin treatment for anxiety syndromes in schizophrenia may be effective and tolerable, and that further research is needed.

Tüm WCP 2026 özetleri